Market Overview

Reata Pharmaceuticals: Q2 Earnings Insights


Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 7.89% year over year to ($1.23), which beat the estimate of ($2.84).

Revenue of $3,073,000 decreased by 60.77% from the same period last year, which beat the estimate of $1,040,000.


Earnings guidance hasn't been issued by the company for now.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $257.96

52-week low: $70.00

Price action over last quarter: down 5.64%

Company Overview

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.


Related Articles (RETA)

View Comments and Join the Discussion!

Posted-In: Earnings News